



PATENT APPLICATION

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q88235

Kazufumi YAZAKI, et al.

Appln. No.: 10/538,291

Group Art Unit: Not Yet Assigned

Confirmation No.: 9414

Examiner: Not Yet Assigned

Filed: June 10, 2005

For:

METHOD FOR SELECTING ESCHERICHIA COLI STRAIN WHICH HIGHLY EXPRESSES EXOGENOUS GENES, ESCHERICHIA COLI MUTANT STRAINS SELECTED BY THIS METHOD AND PROCESS FOR PRODUCING ENZYMES

AND COMPOUNDS USING THE SAME

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

MAIL STOP MISSING PARTS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This paper is in response to the NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES, dated March 9, 2006, issued in the above-referenced patent application.

The Notification to Comply indicates that the present application fails to comply with the requirements of 37 C.F.R. §§1.821-1.825, and specifically that Applicants must provide:

(1) a computer readable form of the Sequence Listing, and (2) a statement that the content of the sequence listing recorded in computer readable form is identical to the written, paper version of the sequence listing.

Response To Notification To Comply With Requirements For Patent Application Containing Nucleotide And/Or Amino Acid Sequence Disclosures

USSN 10/538,291

Accordingly, Applicants include herewith a paper copy of a Substitute Sequence

Listing and a copy of the same in computer readable form, along with a Statement to Support

Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825. A copy of the

Notification to Comply is also submitted herewith.

Applicants respectfully request entry of the substitute Sequence Listing into the

pending application.

Applicants assert that this Response to the Notification to Comply and the enclosures

are being timely filed, and that the enclosures bring the present application in full compliance

with the requirements of 37 C.F.R. §§1.821-1.825.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060 Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373
CUSTOMER NUMBER

Date: April 4, 2006

Registration No. 51,793

2



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

I.A. FILING DATE

12/11/2003

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO. 10/538,291 Kazufumi Yazaki Q88235 INTERNATIONAL APPLICATION NO. PCT/JP03/15882

23373 SUGHRUE MION, PLLC 2100 PENNSYLVANIA AVENUE, N.W. SUITE 800 WASHINGTON, DC 20037

DOCKETED

MAR 2 1 2006

CONFIRMATION NO. 9414 371 FORMALITIES LETTER *OC000000018180617*

PRIORITY DATE

12/12/2002

Date Mailed: 03/09/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37.CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

1 450 2 01 2

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

SHAKEEL AHMED

Telephone: (703) 308-9140 EXT 208

PART 1 - ATTORNEY/APPLICANT COPY

	······································	
U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/538,291	PCT/JP03/15882	Q88235

FORM PCT/DO/EO/922 (371 Formalities Notice)